GSK plc 6-K, filed Mar 9, 2021
GSK plc (GSK)
6-K
2021-03-09
For: 2021-03-09
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on March 9, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Publication of Annual Report 2020
The Company has today published on its
website www.annualreport.gsk.com its
Annual Report for the year ended 31 December 2020 ('Annual Report
2020').
A hard copy version of the Annual Report 2020 and the Notice of
Annual General Meeting 2021 ('AGM Notice') will be sent to those
shareholders who have elected to receive paper communications on or
about 30 March 2021. The AGM Notice will be made available to
shareholders who have not elected to receive paper communications
on the same date.
In compliance with Listing Rule 9.6.1R of the UK Financial Conduct
Authority ('FCA'), the Annual Report 2020 will be submitted to the
UK Listing Authority and will shortly be available for inspection
at the National Storage Mechanism (NSM) https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The information included in the unaudited preliminary results
announcement released on 3 February 2021, together with the
information in the Appendices to this announcement which is
extracted from the Annual Report 2020, constitute the materials
required by the FCA's Disclosure Guidance and Transparency Rule
6.3.5R. This announcement is not a substitute for reading the
Annual Report 2020 in full. Page and note references in the
Appendices below refer to page and note references in the Annual
Report 2020.
V A Whyte
Company Secretary
9 March 2021
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those set out in Appendix A of
this announcement. GSK also refers investors to the cautionary
statement on the inside back cover of the Annual Report
2020.
Brand names
Brand names appearing in italics throughout this announcement are
trademarks either owned by and/or licensed to GlaxoSmithKline or
associated companies.
APPENDIX A
Principal risks and uncertainties
We outline below the principal risks and uncertainties relevant to
GSK's business, financial condition and operations that may affect
our performance and ability to achieve our objectives. These are
the risks that we believe could cause our actual results to differ
materially from expected and historical results.
In 2020 Board oversight was extended beyond the Audit & Risk
Committee, to include more involvement from the Corporate
Responsibility Committee and Science Committee. These committees
considered GSK's risks and the strategies used to address them. In
doing so they drew on annual business unit risk and assurance
update reports, strategy papers for our most significant risks, and
the Corporate Executive Team's (CET's) annual risk
review.
During the year we further developed our risk management framework,
moving from annual to quarterly upwards reporting for most of our
principal risks. This has enabled the Risk Oversight and Compliance
Council to oversee risk in a more dynamic way. We continued to
evolve how we report new and emerging risks and external
environmental insights. We also made reporting more data driven,
with key risk indicators enabling more agile risk management
strategies. In addition, risks and mitigations relating to COVID-19
were incorporated within our most significant risks, to complement
the pandemic risks identified and managed by the Global Issues
Management Team and reported to the CET.
We are required to comply with a broad range of laws and
regulations which apply to the research and development,
manufacturing, testing, approval, distribution, sales and marketing
of pharmaceutical, vaccine and consumer healthcare products. These
affect the cost of product development, the time required to reach
the market and the likelihood of doing so successfully on an
uninterrupted basis.
As rules and regulations change, government interpretation evolves,
and our business activities develop, the nature of a particular
risk may also alter. Changes to certain regulatory regimes may be
substantial. Any alteration in, and failure to comply with,
applicable laws and regulations could materially and adversely
affect our financial results.
Similarly, our global business exposes us to litigation and
government investigations, including but not limited to product
liability litigation, patent and antitrust litigation and sales and
marketing litigation. Litigation and government investigations,
including related provisions we may make for unfavourable outcomes
and increases in related costs such as insurance premiums, could
also materially and adversely affect our financial
results.
More detail on the status and various uncertainties in our
significant unresolved disputes and potential litigation is set out
in Note 46 'Legal proceedings'.
UK regulations require a discussion of the mitigation activities a
company takes to address principal risks and uncertainties. Below
is a description of each of our principal risks with a summary of
the activities that we take to manage each risk across our
businesses. They are not listed in order of
significance.
Patient safety
Risk definition
Failure to appropriately collect, review, follow up, or report
human safety information (HSI), including adverse events from all
potential sources, and to act on any relevant findings in a timely
manner.
Risk impact
Our ability to effectively collect, manage and analyse safety
information associated with our products enables us to conduct
robust safety signal detection activities. This, in turn, ensures
we make decisions based on the most up-to-date risk/benefit profile
of our products and take all appropriate measures to safeguard
patients and consumers. If we do not effectively manage risks to
our patient safety activities, the most serious repercussion could
be harm to patients. This could also lead to reputational damage,
product-related litigation, governmental investigation and
regulatory action, including fines, penalties and even the loss of
product marketing authorisation.
Context
Our licence to operate depends on our compliance with global
pharmacovigilance requirements. We are fully accountable for
safeguarding patients and complying with global regulations.
However, we augment our pharmacovigilance capabilities by using
third parties, and continue to seek innovative solutions (e.g.,
automation and machine learning) for improved patient safety
management through more efficient, reliable and accurate data
collection and interrogation.
We collect information on the safety and efficacy of our products
in humans during clinical development and gain more comprehensive
information on real-world use once our products are on the market.
Safety information is not only obtained by our own ongoing safety
surveillance activities; external parties also analyse
publicly-available clinical trial results or other data. The
variety of sources and the increasing volume of safety data in the
setting of variable and complex global regulations present new and
evolving challenges to how we conduct pharmacovigilance. For
example, we must collect sensitive health information to develop
robust product safety profiles while ensuring adherence to
increasingly stringent global privacy regulations and remaining
vigilant to the threat of cyberattacks.
As a result of the COVID-19 pandemic, GSK's Safety organisation and
our third parties quickly and effectively adopted new ways of
working which did not impact patient safety. However, the urgent
need for effective treatment and prevention of COVID-19, and the
political discourse around developing such treatment and
prevention, increased regulatory, governmental and public scrutiny
on how our industry ensures, through development and regulatory
measures, the safety and efficacy of medicines and vaccines. This
environment could undermine regulatory, governmental and public
trust in medicines for treating COVID-19. This may, in turn,
negatively influence healthcare decisions for other diseases,
leading to reputational damage or product liability
lawsuits.
Mitigating activities
Our Chief Medical Officer (CMO) is accountable for the Patient
Safety enterprise risk and human safety matters, in collaboration
with the Head of Global Safety and with support from business
unit-specific CMOs. A cross-enterprise safety governance board
oversees implementation of our control framework, including risk
management. A Global Safety Board and subsidiary business
unit-specific product safety boards ensure that human safety is
addressed proactively throughout a product's
lifecycle.
Our global policy on management of human safety information
requires that all employees immediately report issues relating to
the safety of our products. Our Third-Party Oversight framework
ensures that third parties at risk of encountering human safety
information are identified and trained appropriately.
Safety information for all products and from all sources is
collected, processed, reported, analysed and followed up in
compliance with global regulations. This information allows us to
detect safety signals for our products and take timely action on
information that changes a product's risk/benefit profile. Proposed
actions are discussed with regulatory authorities and can include
updating the prescribing information, communicating with healthcare
providers, restricting product prescribing/availability to help
assure safe use, and carrying out further clinical trials. In
certain cases, it may be appropriate to stop clinical trials or to
withdraw a product from the market.
In 2020 we embedded changes to our central and local safety
departments, with increased support for core pharmacovigilance
activities from third-party vendors. Our operating model was tested
by the pandemic and, while areas for improvement were identified in
terms of vendor flexibility and capacity, we adapted quickly and
were at full operational capacity in the second half of the year
with no impact on patient safety. We are implementing a new safety
signal management tool, have leveraged automation where possible
for case processing, and are preparing for the integration of the
Pfizer Consumer Healthcare safety database. In 2021 we will further
refine the global Pharmacovigilance organisation to deliver
additional efficiencies, including a focus on advancing innovation
and automation.
Product quality
Risk definition
Failure
by GSK, its contractors or suppliers to ensure:
- Appropriate
controls and governance of quality in product
development;
- Compliance
with good manufacturing practice or good distribution practice
regulations in commercial or clinical trials manufacture and
distribution activities;
- Compliance
with the terms of GSK product licences and supporting regulatory
activities.
Risk impact
A failure to ensure product quality could have far reaching
implications in patient and consumer safety, product launch delays,
drug shortages and product recalls, as well as having regulatory,
legal and financial consequences. These could materially and
adversely affect GSK's reputation and financial
results.
Context
The external environment for product quality remains
challenging.
The European Medicines Agency (EMA) is about to implement two new
sets of requirements. In May 2021, EMA regulations covering the
licensing of medical devices will become effective. The new Annex 1
Guidance for the Manufacture of Sterile Medicinal Products is also
due for release. GSK is preparing to implement both sets of
requirements.
We are reviewing the manufacturing processes for all products to
identify the risks for the presence of nitrosamine impurities, to
comply with updated regulatory requirements. This work will
continue through 2021. Where necessary we will mitigate any
identified risks.
GSK is increasingly using new technology to enhance the manufacture
and testing of our products, for example, we are continuing to
deploy new electronic documentation systems and advanced laboratory
information management tools. The threat of cyberattacks remains a
key risk to the integrity of product quality data and its audit
trail.
Significant changes are taking place in GSK as we implement our new
organisational alignments and strategy. These changes are assessed
by our quality organisations to make sure our quality procedures
and governance can facilitate the strategy, while also ensuring
that no unintended consequences increase our product quality
risk.
Mitigating activities
An extensive global network of quality and compliance
professionals, from site to senior management level, is aligned
with each business unit to provide oversight and assist with the
delivery of quality performance and operational compliance. Such
management oversight is accomplished through a hierarchy of quality
councils, an independent chief product quality officer and a global
product quality office that oversee product quality risk across the
company.
We have developed and implemented a single quality management
system that defines the quality standards and systems for our
businesses associated with pharmaceutical, vaccine and consumer
healthcare products, and for clinical trial materials. This system
has a broad scope and is applicable throughout the product
lifecycle, from R&D to mature commercial supply. It is
augmented by a consolidation of numerous regulatory requirements
from markets across the world, which assures it meets external
expectations for product quality in the markets we supply. Our
system is based on the internationally-recognised principles from
the ICH Q10 pharmaceutical quality system framework.
Our quality management system is routinely updated to ensure it
keeps pace with the evolving external regulatory environment and
new scientific understanding of our products and processes. As part
of our drive to continually improve the operational deployment of
our quality management system, we are making our policies and
procedures simpler to understand and implement and adopting
innovative tools to give a more user-friendly experience. Staff
members are regularly trained in regulatory expectations and
learnings from inspections and existing procedures to ensure
continued maintenance of Current Good Manufacturing Practice
standards.
We have implemented a risk-based approach to assessing and managing
third party suppliers that provide materials used in our finished
products. Contract manufacturers that make our products are
expected to comply with GSK standards and are regularly audited to
provide assurance that they do.
Product incident committee processes are in place to investigate
product issues and make recommendations on remediation activities
including, where necessary, the recall of products to protect
patients and consumers. An established complaint process also
ensures GSK responds appropriately to product quality issues raised
by patients and customers.
Independent functions review and triage allegations of
non-compliance or misconduct received through formal and informal
'Speak Up' channels. Global disciplinary and enforcement procedures
apply to any breaches of our standards, and are initiated, as
appropriate, following investigations.
We leverage key risk indicators to support risk management
activities and provide GSK's Corporate Executive Team and Risk
Oversight and Compliance Council with an integrated assessment of
product quality performance.
Financial controls and reporting
Risk definition
Failure to comply with current tax laws or incurring significant
losses due to treasury activities; failure to report accurate
financial information in compliance with accounting standards and
applicable legislation.
Risk impact
Non-compliance with existing or new financial reporting and
disclosure requirements, or changes to the recognition of income
and expenses, could expose GSK to litigation and regulatory action
and could materially and adversely affect our financial results. In
the current global pandemic, there can be significant changes at
short notice. Failure to comply with changes in the substance or
application of the laws governing transfer pricing, dividends, tax
credits and intellectual property could also materially and
adversely affect our financial results.
Inconsistent application of treasury policies, transactional or
settlement errors, or counterparty defaults could lead to
significant losses.
Context
We are required by the laws of various jurisdictions to publicly
disclose our financial results and events that could materially
affect the Group's financial results. Regulators routinely review
the financial statements of listed companies for compliance with
new, revised or existing accounting and regulatory requirements. We
believe that we comply with the appropriate regulatory requirements
concerning our financial statements and the disclosure of material
information, including any transactions relating to business
restructuring such as acquisitions and divestitures. However,
should we be subject to an investigation into potential
non-compliance with accounting and disclosure requirements, this
could lead to restatements of previously-reported results and
significant penalties.
Our Treasury group deals daily in high value transactions, mostly
foreign exchange and cash management transactions. These
transactions involve market volatility and counterparty
risk.
The Group's effective tax rate reflects the locations of our
activities and the value they generate, which determine the
jurisdictions in which profits arise and the applicable tax rates.
These may be higher or lower than the UK statutory rate and may
reflect regimes that encourage innovation and investment in R&D
by providing tax incentives which, if changed, could affect GSK's
tax rate. In addition, the worldwide nature of our operations means
that our cross-border supply routes, necessary to ensure supplies
of medicines into numerous countries, can result in conflicting
claims from tax authorities as to the profits to be taxed in
individual countries. This can lead to double taxation, with
profits taxed in more than one country. The complexity of tax
regulations also means that we may occasionally disagree with tax
authorities on the technical interpretation of a particular area of
tax law. The tax charge included in our financial statements is our
best estimate of tax liability pending any audits by tax
authorities.
We expect there to be a continued focus on tax reform, driven by
initiatives of the OECD and the EC to address the tax challenges
arising from digitalisation of the economy. Together with domestic
initiatives around the world, these may result in significant
changes to established tax principles and an increase in tax
authority disputes. Regardless of their merit or outcomes, these
may be costly, divert management attention and adversely impact our
reputation and relationship with key stakeholders.
Mitigating activities
Financial results are reviewed and approved by regional management,
before being reviewed by GSK's Group Financial Controller and Chief
Financial Officer (CFO). This allows our Financial Controller and
CFO to assess the evolution of the business over time, and to
evaluate its performance to plan. Significant judgements are
reviewed and confirmed by senior management. Technical or
organisational transformation, newly acquired activities and
external risks, such as the COVID-19 pandemic, are integrated into
risk assessments and appropriate controls and reviews are
applied.
We maintain a control environment designed to identify material
errors in financial reporting and disclosure. The design and
operating effectiveness of key financial reporting controls are
regularly reviewed by management and tested by external third
parties. A minimum standard control set is in place for all finance
locations, irrespective of size, which is reviewed by management
and monitored independently. This provides us with the assurance
that controls over key financial reporting and disclosure processes
have operated effectively. Our Global Finance Risk Management and
Controls Centre of Excellence provides extra support during
significant transformations, such as system deployment or
management/structural reorganisations. We also add operational
resources to ensure processes and controls are maintained during
such changes. We have introduced additional risk mitigation by
amending the programme timelines of system upgrades to optimise
delivery.
The Disclosure Committee, reporting to the Board, reviews GSK's
quarterly results and annual report and, in consultation with its
legal advisors, throughout the year determines whether it is
necessary to disclose publicly information about the Group through
stock exchange announcements. We keep up-to-date with the latest
developments in financial reporting requirements by working with
our external auditor and legal advisors.
The Treasury management group meets regularly to seek to ensure
that liquidity, interest rate, counterparty, foreign currency
transaction and foreign currency translation risks are all managed
in line with the conservative approach detailed in the associated
risk strategies and policies adopted by our Board.
Counterparty exposure is subject to defined limits approved by the
Board for both credit rating and individual counterparties. A
corporate compliance officer, operating independently of Treasury,
oversees Treasury's role in managing counterparty risk in line with
agreed policy. Further details on mitigation of Treasury risks can
be found on pages 214 to 217, Note 43 'Financial instruments and
related disclosures'.
GSK manages tax risk through robust internal policies, processes,
training and compliance programmes. We seek to maintain open and
constructive relationships with tax authorities worldwide. We
monitor government debate on tax policy in our key jurisdictions so
that we can understand and share an informed point of view
regarding any potential future changes in tax law. Where relevant,
we provide pragmatic and constructive business input to tax policy
makers, either directly or through industry trade bodies. This
includes advocating reform to support economic growth and job
creation, as well as the needs of our patients and other key
stakeholders. We submit significant tax decisions to our Tax
Governance Board which meets quarterly and is made up of senior GSK
Finance employees.
Our tax affairs are managed on a global basis by a team of tax
professionals, led by the Global Head of Tax, who work closely with
the business on a day-to-day basis. The Global Tax team is suitably
qualified for the roles they perform, and we support their training
needs so they can provide up to date technical advice in line with
their responsibilities.
We submit tax returns according to statutory time limits and engage
proactively with tax authorities to seek to ensure our tax affairs
are current, entering into continuous audit programmes and advance
pricing agreements where appropriate. These arrangements provide
long-term certainty for both tax authorities and GSK over the tax
treatment of our business, based on full disclosure of all relevant
facts. We seek to resolve any differences of interpretation in tax
legislation with tax authorities in a cooperative manner. In
exceptional cases, we may have to resolve disputes through formal
proceedings.
Anti-bribery and corruption (ABAC)
Risk definition
The
ABAC risk comprises five sub-risk areas:
- Bribery
of public officials by GSK;
- Bribery
of commercial and other non-public entities by GSK;
- Bribery
by third parties acting on behalf of GSK;
-
GSK employees receiving and/or requesting bribes and/or other undue
personal benefit;
- Other
corruption-non-compliance with laws and regulations related to
money laundering or facilitation of tax evasion by third
parties/clients/partners.
Risk impact
Failure to mitigate this risk could expose the Group and associated
persons to governmental investigation, regulatory action, and civil
and criminal liability and may compromise the Group's ability to
supply its products under certain government contracts. In
addition, failure to prevent bribery or corruption could have
substantial implications for GSK's reputation and the credibility
of senior leaders and might erode investor confidence in our
governance and risk management. It could also lead to legal and
financial penalties.
Context
The overall environment for ABAC remains challenging. Countries are
holding individuals, as well as corporations, accountable by
increasing the employer duty of care. Divergence of legislation,
increasing political protectionism, social inequality and pricing
pressures are making compliance harder. Society is holding
corporations to ever higher standards, with technology providing a
rapid and anonymous avenue for dissemination of previously
confidential information and even for damaging false
reports.
Enforcement actions and penalties have increased across the globe
with the focus on use of third-party intermediaries. Proposed EU
legislation would require businesses to carry out due diligence on
potential human rights and related-environmental impacts of their
operations and supply chains, imposing a legal standard of care. In
addition, the impact of COVID-19 on businesses, including
disruptions in manufacturing, the supply chain, import/export and
travel, etc., could increase the risk of bribery and
corruption.
Supportive aspects of the external environment include an increase
in transparency and collaboration among enforcement authorities
with the aim of reducing bribery and corruption globally. Advances
in technology are also providing better platforms to streamline
processes and detect potential issues.
Mitigating activities
We have an enterprise-wide ABAC programme designed to ensure
compliance with our ABAC policies and mitigate the risk of bribery
and corruption. It builds on our business standards, values and
expectations to form a comprehensive and practical approach to
compliance that is flexible to the evolving nature of our
business.
Programme governance is provided through enterprise risk management
overseen by GSK's ABAC Governance Board which includes
representation from key functional areas.
We have appropriate controls in place around transactions and
payments to third parties, such as training, awareness raising and
strong monitoring. We plan to continue with pre- and
post-transaction ABAC due diligence, to increase the capabilities
in the business on monitoring, oversight and red flag resolution of
third parties, and to review controls and accountabilities of
government officials. We continue to assess and understand our
money laundering risk exposure and mitigate any existing
risk.
Our Code of Conduct, values and expectations, and commitment to
zero tolerance towards bribery and corruption are integral to how
we mitigate this risk. In light of the complexity and geographic
breadth of the risk, we constantly evolve our oversight of
activities and data; reinforce to our workforce GSK's clear
expectations regarding acceptable behaviours; and maintain regular
communications between the centre and local markets.
Our ABAC programme is built on best in class principles and is
subject to ongoing review and development. It provides us with the
basis from which we seek to manage the risk from both top down and
bottom up. For example, the programme comprises top-level
commitment from our Board and leadership, and a data analytics
programme to create and embed local key risk indicators to enable
targeted intervention and risk management activities.
The programme is underpinned by a global ABAC policy, and other
written standards, that address commercial and other practices that
give rise to ABAC risk. In addition, the programme
mandates enhanced controls over interactions with government
officials and during business development transactions. Controls in
our ABAC policy establish due diligence requirements for the
engagement of third parties.
We have a dedicated team responsible for the implementation and
evolution of the ABAC programme in response to developments in the
internal and external environment. The ABAC team continually works
with other groups across the enterprise to address and improve
controls and monitoring requirements. The team's work is
complemented by independent oversight and assurance from the Audit
and Assurance and independent business monitoring teams. Issues
identified during oversight and assurance exercises, and from
investigations, are used to identify areas for specific
intervention in the markets and to continuously improve the
programme.
We periodically provide mandatory ABAC training to employees and
relevant third parties in accordance with their roles and
responsibilities and the risks they face.
We continually benchmark our ABAC programme against those of other
large multinational companies and use external expertise and
internal insights to drive improvements.
Formal and informal 'Speak Up' channels are available to report
misconduct or non-compliance. Allegations of non-compliance are
reviewed and triaged by the central investigations team and
allocated for investigation as appropriate.
Commercial practices and pricing
Risk definition
Failure to engage in commercial activities that are consistent with
the letter and spirit of the law, industry regulations, or the
Group's requirements relating to sales and promotion of our
medicines and vaccines; appropriate interactions with healthcare
professionals/organisations and patients; legitimate and
transparent transfers of value; and pricing and competition (or
antitrust) regulations in commercial practices, including trade
channel activities and tendering business.
Risk impact
Failure to engage in commercial activities that are consistent with
the letter and spirit of the law, industry regulations, or the
Group's requirements relating to sales and promotion of medicines
and vaccines; with appropriate interactions with healthcare
professionals (HCPs), organisations and patients; with legitimate
and transparent transfers of value; and with pricing and
competition (or antitrust) regulations in commercial practices,
including trade channel activities and business tendering, could,
materially and adversely affect our ability to deliver our strategy
and long term priorities. Additionally, it may result in incomplete
awareness of the risk/benefit profile of our products and possibly
suboptimal treatment of patients and consumers; governmental
investigation, regulatory action and legal proceedings brought
against the Group by governmental and private plaintiffs which
could result in government sanctions, and criminal and/or financial
penalties. Any practices that are found to be misaligned with our
values could also result in reputational harm and dilute trust
established with external stakeholders.
Context
We continue to evolve our business operations to operate globally
in a highly regulated and extremely competitive biopharma industry,
where our peers may make significant product innovations and
technical advances and intensify price competition. In the Consumer
Healthcare marketplace, where our partners are classic retail,
pharmacies and, increasingly, online platforms, we face similarly
robust competition. In this challenging environment, to achieve our
strategic objectives, we must continue to develop commercially
viable new products and deliver additional uses for existing
products that address the needs of patients, consumers, HCPs and
payers.
In common with other pharmaceutical, vaccine and consumer
healthcare companies we are embracing opportunities in an evolving
digital landscape while facing uncertain market conditions due to
the global COVID-19 pandemic and continued downward price pressure
in major markets.
Developing new pharmaceutical, vaccine and consumer healthcare
products is a costly, lengthy and uncertain process. A candidate
product may fail at any stage, including after the investment of
significant economic and human resources. Our competitors' products
or pricing strategies, or our potential failure to develop
commercially successful products or deliver additional uses for
existing products, could materially and adversely affect our
ability to achieve GSK's strategic objectives.
We are committed to the ethical and responsible commercialisation
of our products in support of our purpose to improve the quality of
human life by enabling people to do more, feel better, and live
longer. To accomplish this purpose, we engage the healthcare
community in various ways to provide important information about
our medicines and vaccines.
By promoting our approved products, we seek to ensure that HCPs
globally have access to the information they need, that patients
and consumers have the facts and products they require, and that
products are prescribed, recommended or used in a manner that
provides maximum healthcare benefits. We are committed to
communicating information related to our approved products in a
responsible, legal and ethical manner.
Mitigating activities
Our strategic objectives are designed to ensure we achieve our
purpose. We continue to strive for new product launches that are
competitive and resourced effectively, and to ensure that a healthy
proportion of Group sales come from new products or
innovations.
By establishing new products that meet the price expectations of
patients, consumers, HCPs, payers, shareholders and the community
we are able to maintain a strong global business and remain
relevant to the needs of patients and consumers. Our values and
behaviours provide a guide for how we lead and make decisions. We
constantly strive to do the right thing and deliver quality
products and sustain reliable supply to meet customer needs. In
doing so, we seek to ensure our actions reflect GSK's values,
behaviours and purpose.
GSK has acted to enhance and improve our policies and standards,
application of data analytics and our channel activities. We have
developed policies to support the strong growth of our Consumer
Healthcare internet channels and digital marketing activities,
using artificial intelligence-powered tools to improve the
oversight of more than 700 GSK websites. We have also improved the
control framework around reporting of adverse events in the digital
space by upgrading our customer service.
We have policies and standards governing commercial activities that
we undertake or are carried out on our behalf. We have implemented
training of all relevant employees to support the evolution of our
activities. All our commercial activities worldwide must conform to
high ethical, regulatory, and industry standards. Where local
standards differ from global ones, we apply those that are most
stringent. Where the standards of an acquired company or joint
venture partner differ from our global standards, we will remediate
legacy policies and implement revisions so they align.
Our Consumer Healthcare business has harmonised policies and
procedures, to guide regional and global commercial practice
processes, and clarified applicable standards for operations in the
markets in which we operate. We are also reducing our number of
export hubs from more than 20 to five, complemented by a specific
control framework for their activity. In China we have developed a
specific promotion code, to enable responsible business growth and
employee behaviour. In 2020 we trained more than 1,800 employees in
the new code.
GSK's Pharmaceuticals, Consumer Healthcare and Vaccines businesses
have adopted our internal control framework to support its
assessment and management of risks. Business unit risk management
and compliance boards, that manage risks across in-country business
activities, oversee commercial activities and their monitoring
programmes. We continue to improve the framework and culture of our
compliance processes.
All promotional materials and activities must be reviewed and
approved according to our policies and standards and conducted in
accordance with local laws and regulations; these requirements seek
to ensure that such materials and activities fairly represent the
Group's products or services. Consumer Healthcare has deployed a
new copy approval tool to improve controls over important
promotional activity. Where necessary, in the event of
misconduct, we have disciplined employees, up to and including
termination of contract, and clawed back remuneration from senior
management.
We have continued to evolve our incentive programme for
Pharmaceuticals and Vaccines sales representatives to better
recognise and reward individual effort. In specialty care, for
example, the capped variable pay element of representatives'
compensation is evaluated on the basis of individual sales targets.
This approach, which has been implemented in more than 30 markets,
is supported by a comprehensive training, control, and monitoring
framework to ensure full alignment with GSK's values-based approach
to HCP engagement.
We allow fair market value payments to be made by GSK to expert
practitioners to speak about our innovative medicines and vaccines
in most countries in North America, Europe and Asia Pacific during
a restricted time period in a product's lifecycle. Controls and
training ensure appropriate oversight across markets. Where
permitted we report payments to individual HCPs as part of our
commitment to transparency and responsible disclosure.
Consumer Healthcare has been a key driver in the development of an
ethical code for the Global Self-Care Federation, setting
principles for promotion to healthcare practitioners and pharmacy
staff.
GSK is committed to complying with all applicable sanctions laws
and regulations and has deployed a programme to enable management
of sanctions risk. The programme, led by GSK Finance, is made up of
various systems and controls including, but not limited to,
policies and procedures, training and awareness, screening,
monitoring and risk reporting.
Non-promotional engagement
Risk definition
Failure to engage in non-promotional activities that are consistent
with external regulations, internal policies, and GSK values
regarding scientific engagement with healthcare professionals and
patients, including i) communications relating to our medicines or
associated disease areas; ii) appropriate conduct of interactions;
and iii) legitimacy and transparency of those
interactions.
Risk impact
Without controls in place, the risk could result in reputational
damage, governmental or regulatory investigations (e.g., regarding
real, perceived or disguised promotion including off-label and
prior-authorisation promotion, and real or perceived provision of
medical advice), criminal investigations and penalties, civil
litigation or competitor complaints affecting our financial results
and reducing the trust of the general public, patients, healthcare
professionals, payers, regulators and governments. At the same
time, failure to engage fully and appropriately could also result
in reputational damage, patient harm and financial
loss.
Context
Non-promotional engagements are diverse activities directed at
healthcare professionals, as well as patients, payers and other
stakeholders. They aim to improve patient care through the exchange
or provision of knowledge on the use of GSK medicines and vaccines
and about related diseases. Non-promotional engagement with
external stakeholder groups is vital to GSK, as a research-based
healthcare company, and necessary for scientific and medical
advances. We expect our non-promotional activities to be
scientifically sound and accurate, conducted ethically and
transparently and compliant with applicable codes, laws and
regulations. However, non-promotional engagements are largely
unregulated. Therefore, measured risk taking, rooted in sound
values, and principles-based decision making, training,
communication and monitoring are key to managing the risk and
enabling full and appropriate engagement.
Mitigating activities
Our Chief Medical Officer (CMO) oversees all non-promotional
engagement as enterprise risk owner.
The GSK Code of Practice is the key internal policy for
non-promotional engagement activities. These activities include,
among others, scientific interactions, support of medical and
disease education, advice seeking, scientific communication of
our research, and disease awareness for the general public. In 2020
we launched a revised Code of Practice supported by revised
Standard Operating Procedures, in order to become a more agile and
innovative organisation.
In 2020 COVID-19 resulted in a significant increase in virtual
engagements (e.g., with external experts, advisory boards, patient
advocacy, patient engagements and congresses). We further
modernized our practices and applied our internal principles and
policies to this rapidly changing and growing environment. We are
evolving our employee training so that our people understand the
risk associated with non-promotional activities, and conduct them
in compliance with GSK's values and policies, local laws and
regulations. This training must be extended to third parties who
support non-promotional activities to ensure they also understand
and comply with the risk mitigation to ensure non-promotional
activities are not, or do not appear as, promotion. We continue to
build effective management monitoring systems and apply key risk
indicators for managing non-promotional engagement.
Privacy
Risk definition
The failure to collect, secure, use and destroy Personal
Information (PI) in accordance with data privacy laws can lead to
harm to individuals (e.g. financial, stress, prejudice) and GSK
(e.g. fines, operational, financial and reputational).
Risk impact
Non-compliance with data privacy laws globally could lead to harm
to individuals and GSK. It could also damage trust between GSK and
individuals, communities, business partners and government
authorities.
Many countries have increased the enforcement powers of their data
protection authorities by allowing them to impose significant
fines, impact cross-border data flows, or temporarily ban data
processing. Many new country laws also give individuals the right
to bring collective legal actions against companies like GSK for
failure to comply with data privacy laws.
Context
Data privacy legislation is diverse with limited harmonisation or
simplification. It is challenging for multinationals to standardise
their approach to compliance with data privacy laws. Governments
are enforcing compliance with data privacy laws more rigorously.
The focus on the ethical use of personal information is growing,
over and above compliance with data privacy laws, due to an
increase in the volume of data processed and advances in
technology.
Workforce protection and effective privacy controls for research
during the COVID-19 pandemic are creating unique challenges.
Additionally, new data privacy laws, enforcement activities and
court decisions - like the Court of Justice of the European Union
ruling for Schrems II - are creating uncertainties for
international data transfers and potential localisation
requirements.
Mitigating activities
The Group's Chief Compliance Officer is also the chair of our
Privacy Governance Board, which oversees GSK's overall data privacy
operating model. Each GSK business area has appointed a risk owner
accountable for overseeing its privacy risks, who is supported by
privacy leaders within their business. In some countries data
privacy laws require a data protection officer (DPO) to be
appointed. GSK has appointed a single DPO for the EU, who is
represented and supported in specific countries by country privacy
advisors.
Our Chief Compliance Officer is GSK's enterprise risk owner (ERO).
The ERO has appointed a delegate risk owner, the global privacy
officer (GPO), who has day-to-day accountability for designing and
implementing the control framework. The GPO co-leads the
cross-functional Privacy Centre of Excellence, together with the
Global Privacy Counsel. They are supported by privacy officers,
privacy counsel, and multiple country privacy advisors (who are
familiar with local privacy regulations).
GSK has evolved the initial control framework implemented for the
EU General Data Protection Regulation into a comprehensive privacy
control framework, based on global privacy principles common across
the global privacy landscape. This global framework has been
deployed in countries exhibiting a need for such a comprehensive
framework, based on factors like robust local privacy legislation,
established data protection authorities, and GSK footprint. Beyond
those countries, we have started preparations to involve, resource
and educate the employees in remaining undeployed countries with a
GSK footprint.
Our
Privacy Centre of Excellence is responsible for:
- operating
and improving the centralised global privacy control
framework;
- continuously
assessing and providing relevant and proportionate controls and aid
to non-deployed markets;
- monitoring
new, or changing, laws and adapting the privacy framework
accordingly; and
- deploying
a comprehensive training programme to drive greater awareness and
accountability for managing personal information across the entire
organisation.
We
certify key GSK privacy network roles with an accredited
international privacy association.
We
continuously improve our processes, such as issue identification,
reporting and handling, through monitoring. The Privacy Centre of
Excellence is involved in new business development opportunities at
an early stage to ensure appropriate due diligence is performed and
the right steps are taken when onboarding or splitting off a
business unit.
Research practices
Risk definition
Research Practices risk is the failure to adequately conduct
ethical and sound pre-clinical and clinical research. In addition,
it is the failure to engage in scientific activities that are
consistent with the letter and spirit of the law and industry, or
the Group's requirements. It comprises the following sub-risks:
Non-Clinical & Laboratory Research; Human Subject Research;
Data Integrity; Care, Welfare & Treatment of Animals; Human
Biological Samples Management; Data Disclosure; Regulatory Filings
& Engagement; and Patents.
Risk impact
The potential impacts of the risk include harm to human subjects,
reputational damage, failure to obtain the necessary regulatory
approvals for our products, governmental investigation, legal
proceedings brought against the Group by governmental and private
plaintiffs (product liability suits and claims for damages), loss
of revenue due to inadequate patent protection or inability to
supply GSK products, and regulatory action such as fines,
penalties, or loss of product authorisation. Any of these could
materially and adversely affect our financial results and damage
the trust of patients and customers.
Context
Research involving animals can raise ethical concerns. In many
cases, however, research in animals is the only way to investigate
the effects of a potential new medicine in a living body other than
in humans. Animal research provides critical information about the
causes and mechanisms of diseases and therefore remains a vital
part of our research. We continually seek ways in which we can
minimise our use of animals in research, development and testing,
while complying with regulatory requirements and reducing the
impact on the animals used.
Human subject research, including clinical trials in healthy
volunteers and patients, assess and demonstrate an investigational
product's efficacy and safety, or further evaluate the product once
it has been approved. We disclose this research externally,
according to regulations, ethical principles and industry
commitments.
We also work with human biological samples, which are fundamental
to the discovery, development and safety monitoring of our
products. GSK is committed to ensuring that human biological
samples are managed in accordance with relevant laws, regulations
and ethical principles, in a manner that respects the interests of
sample donors.
The integrity and governance of our data is essential to success in
all stages of the data lifecycle, including design, generation,
recording and management, analysis, reporting, storage and
retrieval. Our R&D data are governed by legislation and
regulatory requirements. Data and supporting documents are core
components at various stages of pipeline progression decision
making and form the content of regulatory submissions, publications
and patent filings. Poor data integrity and governance could
compromise GSK's R&D efforts and negatively impact our
reputation.
There are innate complexities and interdependencies in regulatory
filings, particularly given our global R&D footprint. Ever
changing and increasingly stringent submission requirements
continue to increase the complexity of worldwide product
registration. The supply of GSK medicines to patients is dependent
on the ongoing compliance and maintenance of licences across many
geographies, whose requirements and timelines differ. The secure
management of the high volume of lifecycle changes to these
licences, and their renewal, is critical to compliant supply.
Failure to maintain our licences will directly impact patients and
company revenue.
A wide variety of biological materials are used by GSK in the
discovery, research and development of our assets. Through the
Convention on Biological Diversity (CBD) and the Nagoya Protocol,
the international community has established a global framework
regulating access to, and use of, genetic resources of non-human
origin in R&D.
We support the principles of access to, and benefit sharing of,
genetic resources as outlined in the CBD and the Nagoya Protocol.
We also recognise the importance of appropriate, effective and
proportionate implementation measures at national and regional
levels.
Patent rights are awarded to protect innovation and play an
important role in providing a competitive advantage in the market
for a limited period of time. Any loss of patent protection in a
market for GSK's products developed through our R&D - including
reducing the term, availability or scope of patent rights - could
materially and adversely affect our financial results in that
market. Inadequate patent or data exclusivity protection which
could lead, for example, to competition from manufacturers of
generic or biosimilar pharmaceutical products could limit our
opportunity to rely on such markets for future sales growth. This
could also materially and adversely impact our financial
results.
Following expiration of certain intellectual property rights, a
generic or biosimilar manufacturer may lawfully produce a competing
copy of a product. Introduction of generic products typically leads
to a rapid and dramatic loss of sales and reduces our revenues and
margins for our proprietary products.
Mitigating activities
We have an established Office of Animal Welfare, Ethics and
Strategy (OAWES), led by our Chief Veterinary Officer, that
supports the humane and responsible care of animals, carries out
ethical reviews, independent scientific reviews of animal studies,
and shares knowledge and advocates for the application of
non-animal alternatives. The OAWES provides a framework of animal
welfare governance, defines and provides oversight for animal care
and use training, promotes the replacement, refinement and
reduction of animals in research, conducts quality assessments,
manages a programme of external animal diligence, and develops and
deploys strategies on reproducibility of experiments and
translatability to human clinical end points.
GSK's
Chief Medical Officer oversees the following enterprise Medical
Governance Boards:
- The
Human Subject Research Board and Risk Forum provide oversight for
the human subject research that we sponsor and support to ensure it
conforms to ethical, medical and scientific standards
- The
Data Disclosure Board and Risk Forum oversee disclosure of our
sponsored and supported human subject research. We make information
available on our clinical studies, including summaries of the
results - whether positive or negative
We have a global human biological samples management (HBSM)
governance framework to oversee the ethical and lawful acquisition
and management of human biological samples. Our HBSM enterprise
risk management team works to minimise the risks related to the
acquisition, storage, use, transfer, and disposal of human
biological samples.
Enhancing our data integrity controls remains an important
priority. Our data integrity committees provide oversight, with
data integrity quality assurance teams conducting assessments to
provide independent business monitoring of our internal controls
for R&D activities.
The Regulatory Governance Board serves as the global regulatory
risk management and compliance board. It promotes compliance with
regulatory requirements and procedures and oversees Group-wide
written standards for cross-business regulatory processes. A
significant programme is underway to replace and modernise our
regulatory information management systems across GSK.
We established an Access and Benefit Sharing Centre of Excellence
to oversee requirements and enforcement measures for the
acquisition and use of genetic material of non-human origin in line
with the Nagoya Protocol.
Our R&D organisation maintains and controls pre-publication
procedures to guard against public disclosure in advance of filing
patent applications. In addition, because loss of patent protection
can occur due to a lack of data integrity in preparing patent
application data and information, legal experts collaborate with
R&D to support the review process for new patent
applications.
The Research practices risk is overseen by an enterprise framework
that seeks to ensure strengthened governance across R&D in our
Pharmaceuticals, Vaccines and Consumer Healthcare
businesses.
Under the leadership of the Research practices enterprise risk
owner, management of the risk takes a pragmatic approach to
information sharing, streamlining risk identification and
escalation while ensuring ownership stays with the
business.
Environment, health & safety
Risk definition
Failure in management of:
- execution
of hazardous activities;
- GSK's
physical assets and infrastructure;
- handling
and processing of hazardous chemicals and biological
agents;
- control
of releases of substances harmful to the environment in both the
short and long term;
leading to incidents which could disrupt our R&D and Supply
activities, harm employees, harm the communities and harm the local
environments in which we operate.
Risk impact
Failure to manage EHS risks could lead to significant harm to
people, the environment and the communities in which we operate;
fines; inability to meet stakeholder expectations and regulatory
requirements; litigation or regulatory action; and damage to the
Group's reputation, which could materially and adversely affect our
financial results.
Context
GSK is subject to the health, safety and environmental laws of
various jurisdictions. These laws impose duties to protect people,
the environment, and the communities in which we operate, as well
as potential obligations to remediate contaminated sites. Overall,
our control framework for managing EHS risk is
effective.
Mitigating activities
The Corporate Executive Team is responsible for EHS governance and
risk oversight and ensures there is an effective control framework
in place, and in use, to manage the risks, impacts and legal
compliance issues that relate to EHS across each of our businesses.
This includes assigning responsibility to senior managers for
providing and maintaining these controls and ensuring that tiered
monitoring and governance processes are in place within their
businesses. Individual managers seek to ensure that the EHS control
framework is effective and well implemented in their respective
business area, and that it is fully compliant with all applicable
laws and regulations and is adequately resourced, maintained,
communicated, and monitored. Additionally, each employee is
personally responsible for ensuring that they follow all applicable
local standard operating procedures.
Our risk-based, proactive approach is articulated in our global EHS
policy and detailed in our global EHS standards against which we
audit all our operations to ensure compliance. We ensure hazards
are appropriately controlled through the safe design of facilities,
plant and equipment, and by following rigorous procedures that help
us provide effective barriers to protect employees' health and
safety.
Despite our extensive safety programmes, tragically we experienced
two employee fatalities, one at a manufacturing site in Canada and
another in a road traffic accident in India. There was an
additional work-related fatality in Belgium, involving a
construction worker not under GSK's direct supervision. We
conducted extensive investigations into the causes of each fatality
to ensure we could take actions to reduce the risk of similar
tragic incidents occurring. We have developed a safety improvement
plan to further strengthen our existing safety
practices.
Environmental sustainability
Risk definition
Failure in the management of:
- Physical
climate and environmental risks;
- Current
and future regulatory requirements for environmental policies and
taxes;
- Delivery
and performance of management environmental
objectives;
leading to: reduced supply chain resilience; product life cycle
management issues, loss of trust/reputation with employees,
investors, customers, regulators and other stakeholders; increased
costs; loss of sales or market access; negative impacts on the
environment.
Risk impact
GSK recognises that the way we respond to climate change and manage
environmental risks impacts our ability to supply products to
patients and consumers and could lead to harm to the environment
and impact our reputation.
Failure to meet fast-evolving regulatory requirements and
stakeholder expectations could result in litigation or regulatory
actions, which may materially and adversely impact our financial
results.
Context
It is increasingly understood that the effects of climate change
and nature loss, which are themselves interconnected, are impacting
human health. Internal and external expectations for companies to
address their impact on the environment are increasing; as are the
effects of climate change on operational resilience, in regard to
access to energy, water and the natural resources used in products,
along with potential cost increases from any regulatory changes or
environmental taxes.
Mitigating activities
In November 2020, GSK announced a new commitment to have net zero
climate impact and to be net nature positive by 2030. These goals
build on our long-term ambition, as set out in 2010, to reduce our
impact on the environment.
The Corporate Executive Team (CET) is responsible for environmental
sustainability governance and risk oversight. It ensures there is
an effective framework in place, and in use, to manage the risks
across each of our businesses and to deliver on the commitments
made. GSK has a dedicated environmental sustainability enterprise
risk plan in place. The CET's responsibilities include appointing
dedicated senior leaders and resources to provide and maintain risk
controls and ensure that governance processes are established and
effective within their businesses.
We will continue to control antibiotic emissions from manufacturing
effluents at all GSK facilities, and those of our suppliers,
following good operational practice and meeting emission limits as
defined by the AMR Alliance Manufacturing Framework.
We continuously assess our business resilience to climate change
against the Task Force on Climate-related Financial Disclosures
framework guidelines.
We ensure reductions in carbon emissions, energy, water and waste
are delivered and managed by our mature programmes and by including
eco-design considerations into products and packaging.
Information security
Risk definition
The risk that unauthorised disclosure, theft, unavailability or
corruption of GSK's information or key information systems may lead
to harm to our patients, workforce and customers, disruption to our
business and/or loss of commercial or strategic advantage, damage
to our reputation or regulatory sanction.
Risk impact
Failure to adequately protect GSK's information, or key information
systems, may cause harm to our patients, workforce and customers,
disruption to our business and/or loss of commercial or strategic
advantage, regulatory sanction, or damage to our
reputation.
Context
The overall information security environment is challenging,
because of the difficulty of keeping pace with increasingly
sophisticated cyber threats. This is due to many factors including,
the complexity of large regulated organisations; the well-resourced
nature of hacking activities; and the increasing demands for
accountability of data handled by companies. We continue to
reassess GSK's reliance on interconnectivity with third party
contractors, partners and suppliers. The COVID-19 pandemic has
emerged as another significant external factor impacting how
information security is managed at GSK. COVID-19-related threats
include an increase in ransomware attacks against the healthcare
sector, as hackers have used the opportunity to disrupt critical
healthcare operations and, in some cases, seize healthcare research
related to COVID-19 vaccines and treatments.
GSK operates a highly-connected information network which holds
confidential research and development, manufacturing, commercial,
workforce and financial data. This means that our systems and
information have been and will continue to be the target of
cyberattacks. We continue to consolidate information systems to
reduce attack points and enable more focused controls. GSK's
strategic approach to digital analytics will further increase our
dependency on digital assets and distributed data. Our continued
analysis and assessment of GSK's critical data assets and the
threats to those assets will require a continuous re-evaluation of
emerging risks to GSK. Mitigating actions already defined in these
areas includes the secure deployment and operation of GSK resources
in high-risk markets, the risk posed by GSK having data in the
Cloud, and the potential for complexity resulting from agile
business-led IT development across the enterprise.
Mitigating activities
We have a global information security policy and accompanying IT
standards and processes that are supported by a dedicated team and
programme of activity. The GSK Technology, Security and Risk
function provides strategy, direction and oversight. This includes
active monitoring of cybersecurity, while enhancing our global
information security capabilities through an ongoing programme of
investment. In 2020, we made the following significant investments
in mitigation activities, which we will continue to advance in the
coming year:
-
Modernising cyber operations to ensure the timely detection and
response to information security incidents
-
Modernising operational technology (OT) to address the age,
complexity and global footprint of the OT environment in
manufacturing and R&D sites
-
Optimising security architecture to mitigate the risk of network
users using email, externally-connected communications and
removeable media inappropriately, whether intentionally or
unintentionally. We are also continuing to remediate and improve
the control environment for privileged or elevated user rights
across GSK's systems
-
Transferring third party risk management to a managed service
partner. This organisation will process GSK's critical and
sensitive information and support the development of a solution
that will enable us to move all third parties that access our IT
resources remotely to a more secure environment
-
Enabling business performance in high risk markets by assessing
data and information originating in, and flowing to, international
markets where local laws and norms represent a heightened risk to
the confidentiality, integrity and availability of GSK's
operational systems
Supply continuity
Risk definition
Failure to deliver a continuous supply of compliant finished
product; inability to respond effectively to a crisis incident in a
timely manner to recover and sustain critical
operations.
Risk impact
We recognise how important the continuity of supply of our products
is to the patients and consumers who rely on them. A material
interruption of supply could lead to litigation or regulatory
action, including exclusion from healthcare programmes and
financial penalties that might adversely affect the Group's
financial results. GSK's international presence, and those of our
partners, expose our workforce, facilities, operations and IT to
potential disruption from natural events (e.g., storms and
earthquakes), man-made events (e.g., the imposition of trading
barriers at short notice, civil/political unrest, terrorism and
cyberattacks), and public health emergencies (e.g., the global
COVID-19 pandemic). It is therefore vital that we have robust
crisis management and recovery plans in place to manage such
events.
Context
Our supply chain operations are subject to review and approval by
various regulatory agencies that effectively provide our licence to
operate. Failure of our manufacturing and distribution network to
deliver products could lead to litigation or regulatory action,
such as product recalls and seizures, interruption of supply,
delays in approval of new products, and suspension of manufacturing
operations pending resolution of manufacturing or logistics
issues.
We rely on materials and services provided by third party suppliers
to make our products. These include active pharmaceutical
ingredients, antigens, intermediates, commodities, and components
for developing, manufacturing and packaging pharmaceutical, vaccine
and consumer healthcare products. Our third-party oversight
includes the outsourcing of operations, such as contract
manufacturing and clinical research organisations, that provide
manufacturing and support development of key products on our
behalf.
Although we undertake risk mitigation, we recognise that certain
events could still result in delays or service interruptions. We
use effective crisis management and business continuity planning to
ensure the health and safety of our people and to minimise the
impact on supply, by maintaining functional operations in the event
of a natural or man-made disaster, or a public health emergency.
Drug shortages are reported to appropriate regulatory authorities
such as the US Food and Drug Administration for transparency and to
solicit feedback on risk mitigation.
Supply performance expectations increased during the COVID-19
pandemic as governments sought to secure supply for key medicines
and vaccines. We prioritised, and aligned behind, the manufacture
and supply of these pandemic medicines with our suppliers,
leveraging strategic stocks and modifying supply routes to avoid
disrupting the availability of our finished products.
We also participated in the EU's new reporting system for
anticipated drug shortages, introduced during the pandemic to
proactively resolve supply issues before they potentially impacted
hospital intensive care units.
Mitigating activities
The supply chain model adopted in our Pharmaceuticals, Vaccines and
Consumer Healthcare business units is designed to ensure, as far as
possible, the supply, quality and security of our products around
the world.
Supply chain governance committees within each business unit
closely monitor the inventory status and delivery of our products,
with the aim of ensuring that customers have the products they
need. Improved links between commercial forecasting and
manufacturing - made possible by our core commercial cycle -
should, over time, reduce the risk associated with demand
fluctuations and any impact on our ability to supply, or the cost
of write-offs where products exceed their expiry date. Each node of
the supply chain is periodically reviewed to ensure adequate safety
stock, while balancing working capital in our end-to-end supply
chain. Particular attention is placed on mitigating supply risks
associated with medically-critical, high-revenue products and key
new product launches.
We routinely monitor the compliance of external manufacturing
suppliers and service providers to identify and manage risks in our
supply base. Where practical, we minimise our dependence on single
sources of supply for critical items. Where alternative
sourcing arrangements are not possible for certain materials, our
inventory strategy aims to limit the impact and ultimately protect
the supply chain from unanticipated disruption.
We continue to implement anti-counterfeit systems like product
serialisation in accordance with new and emerging supply chain
requirements around the world, such as the EU Falsified Medicines
Directive.
Corporate policy requires each business and functional area head to
ensure effective crisis management and business continuity plans,
including authorised response and recovery strategies, key areas of
responsibility and clear communication routes, are in place before
any business disruption occurs. Corporate Security supports the
business by coordinating crisis management and business continuity
training, facilitating simulation exercises, assessing preparedness
and recovery capability, and providing assurance oversight of GSK's
central repository of plans supporting our critical business
processes.
Each business unit performs risk oversight through their respective
Risk Management and Compliance Board to assure adequate risk
mitigation, including identifying new and emerging threats. For
example, we have taken a coordinated approach to evaluating and
managing the implications for GSK of Brexit.
These activities help ensure that we maintain an appropriate level
of readiness and response capability. We also develop and maintain
partnerships with external bodies, including the Business
Continuity Institute and the UN International Strategy for Disaster
Risk Reduction, which helps improve our business continuity
initiatives in disaster-prone areas and supports the development of
community resilience to disasters.
Transformation
Risk definition
Failure to deliver the plan for successful transformation and
separation of GSK into two competitive standalone companies:
New GSK, a biopharma company, and new Consumer
Healthcare.
Risk impact
The failure to manage the increasing macro level risk due to
COVID-19 in relation to the delivery of the transformation plan
could materially and adversely affect our ability to deliver GSK's
strategy and long-term priorities.
Context
In February 2020, GSK announced a new 'Future Ready' programme to
prepare for its separation into two companies: New GSK, a biopharma
company with an R&D approach focused on science related to the
immune system, the use of genetics and new technologies, and a new
leader in consumer healthcare. As GSK increases investment in
R&D and new product launches, the two-year separation programme
aims to drive a common approach to innovation across modalities
with improved capital allocation; to align and improve the
capabilities and efficiencies of global support functions to
support New GSK; to further optimise the supply chain and
portfolio, including divesting non-core assets; and to prepare
Consumer Healthcare to operate as a standalone company. Once
complete, the outlook of both companies will have been
fundamentally strengthened, making them more efficient, modern and
automated, with future skills and capabilities that will extend
beyond the transition timeline.
Mitigating activities
The Future Ready Office (FRO), established in the fourth quarter of
2019, is accountable for monitoring the progress, performance and
risks associated with creating the two new leading companies. It
reports monthly to the Corporate Executive Team (CET) to ensure
there is enterprise oversight of the plan, using key performance
and risk indicators. In addition, GSK's Chief Executive Officer
(CEO), Chief Financial Officer, Chief Strategy Officer and Head of
FRO meet the leaders of Consumer Healthcare when input and approval
of key design choices for that new company is required. Overall,
the balance between transformation and separation is upheld
through clear governance, joint New GSK and Consumer Healthcare
coordination, rigorous progress tracking and the setting of clear
parameters.
The GSK Board is regularly informed of the Future Ready programme
lead indicators through the CEO Board Report at each Board meeting.
A Transformation and Separation Committee has been established at
Board level to support and advise management's work on transforming
and separating the Group. This committee is chaired by the GSK
Chairman and includes our Senior Independent Director and the
Chairs of the Audit & Risk, Remuneration and Corporate
Responsibility Committees.
APPENDIX B
Directors' responsibility statement
Each of the current Directors, whose names and functions are listed
in the Corporate Governance section of the Annual Report 2020
confirms that, to the best of his or her knowledge:
- the
Group financial statements, which have been prepared in accordance
with IFRS, as adopted pursuant to Regulation (EC) No 1606/2002 as
it applies in the European Union, and IFRS as issued by the IASB,
give a true and fair view of the assets, liabilities, financial
position and profit of the Group; and
- the
Strategic report and risk sections of the Annual Report, which
represent the management report, include a fair review of the
development and performance of the business and the position of the
company and the Group taken as a whole, together with a description
of the principal risks and uncertainties that it
faces.
|
Name
|
Function
|
|
Sir
Jonathan Symonds
|
Non-Executive
Chairman
|
|
Emma
Walmsley
|
Chief
Executive Officer
|
|
Dr Hal
Barron
|
Chief
Scientific Officer and President, R&D
|
|
Iain
Mackay
|
Chief
Financial Officer
|
|
Manvinder
Singh (Vindi) Banga
|
Senior
Independent Non-Executive Director
|
|
Dr
Vivienne Cox
|
Independent
Non-Executive Director and Workforce Engagement
Director
|
|
Lynn
Elsenhans
|
Independent
Non-Executive Director
|
|
Dr
Laurie Glimcher
|
Independent
Non-Executive Director and Scientific & Medical
Expert
|
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director and Scientific & Medical
Expert
|
|
Judy
Lewent
|
Independent
Non-Executive Director
|
|
Urs
Rohner
|
Independent
Non-Executive Director
|
|
Charles
Bancroft
|
Independent
Non-Executive Director
|
APPENDIX C
Related party transactions
At 31 December 2020, GSK owned 32 million shares or 31.6% of
Innoviva Inc. which is a biopharmaceutical company listed on
NASDAQ. GSK began recognising Innoviva as an associate on 1
September 2015. The royalties due from GSK to Innoviva in the year
were £261 million (2019 - £215 million). At 31 December
2020, the balance payable by GSK to Innoviva was £65 million
(2019 - £63 million).
A loan of £3.0 million to Medicxi Ventures I LP remained due
to GSK at 31 December 2020. The loan due from Index Ventures Life
VI (Jersey) LP was repaid in the year. In 2020, GSK increased the
investment in Kurma Biofund II, FCPR by £0.8 million and
Apollo Therapeutics LLP by £2.0 million. Further investments
were also made in Medicxi Ventures I LP of £1.2 million. As
part of the joint venture agreement with Qura Therapeutics LLC, the
Group had an obligation to fund the joint venture $1 million per
quarter up to April 2020. On 26 June 2019, the agreement was
extended for a second five-year period up to April 2025, with both
GSK and its joint venture partner committing additional financial
support in the amount of $20 million. At December 2020, the
outstanding liability due to Qura was $17 million.
Cash distributions were received from our investments in Medicxi
Ventures I LP of £14.5 million and in Index Venture VI
(Jersey) LP of £10.6 million.
The aggregate compensation of the Directors and CET is given in
Note 9, 'Employee costs'.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
|
GlaxoSmithKline plc
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date: March
09, 2021
|
|
|
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
|
|
Victoria Whyte
|
|
|
|
Authorised
Signatory for and on
|
|
|
|
behalf
of GlaxoSmithKline plc
|